Clinical Trials Logo

Recurrent Endometrial Cancer clinical trials

View clinical trials related to Recurrent Endometrial Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02899793 Active, not recruiting - Clinical trials for Recurrent Endometrial Cancer

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Start date: September 2016
Phase: Phase 2
Study type: Interventional

Primary Objectives: To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of pembrolizumab with objective tumor response in patients with persistent, recurrent or metastatic endometrial cancer harboring an ultra-mutated or hyper-mutated (MMR gene-defective) phenotype identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP). To determine the nature and degree of toxicity of pembrolizumab as assessed by CTCAE in patients with persistent, recurrent or metastatic endometrial carcinoma. Secondary Objective(s): To estimate the duration of progression-free survival (PFS) and overall survival (OS).